Newsletter · 2026-07-24 · Ashutosh Agarwal

Novo Drags Lilly to Court as the Obesity War Turns Legal - The Biotech Patent Cliff & M&A - Week of July 24, 2026

The Biotech Patent Cliff & M&A for the week of July 24, 2026. Novo Nordisk sued Eli Lilly over its obesity-drug advertising, Lilly's 12-deal, roughly $23 billion buying spree became the loudest story in pharma, and the cliff-exposed incumbents stayed conspicuously quiet heading into a heavy earnings run.

The Biotech Patent Cliff & M&A

Week of July 24, 2026: Novo Drags Lilly to Court as the Obesity War Turns Legal

TL;DR

• The GLP-1 fight went to the courtroom. Novo Nordisk is suing Eli Lilly, claiming Lilly's ads use an "outdated" head-to-head trial (against Wegovy's old 2.4mg dose, not Novo's new 7.2mg). Wall Street's read, echoed by Jim Cramer, is that it looks like a distraction from a company that has been losing. Lilly is winning the efficacy story; Novo is winning the oral-pill launch (roughly 89% of pill scripts). Neither number changes the cliff math, but the tone is telling.
• Lilly's "Amazonification" is now the loudest story in pharma. Its $3.8B Atai psychedelics buy was its 12th acquisition this year, roughly $23B in upfront M&A in seven months. This is the clearest playbook for filling a cliff: buy relentlessly, early, and across therapy areas, years before your own franchise plateaus.
• The cliff-exposed incumbents were quiet, and that is the signal. Merck lost the Personalis auction (to Tempus, not a rival pharma), Pfizer got branded a "hamster wheel," and Bristol, J&J and AbbVie said nothing new ahead of a heavy earnings run (AZN 7/27, BMY 7/30, ABBV 7/31). The deal machine keeps humming; the buyers who most need it are the ones we heard least from.

What's new

1. Novo sues Lilly, the obesity war becomes a legal war

The single biggest new development this week was not a deal or a data readout. It was a lawsuit, and it was the most-discussed pharma story across podcasts this week.

The dispute is narrow but revealing. As STAT's Elaine Chen laid out on The Readout Loud (episode 410, July 23), Lilly ran a head-to-head trial pitting its drug Zepbound against Wegovy at the 2.4mg dose, Wegovy's highest dose at the time, and Zepbound won. Lilly has been advertising that result everywhere. Novo's complaint: that comparison is now "outdated," because Novo launched a stronger 7.2mg version of Wegovy this year, and there is no head-to-head data pitting that dose against Zepbound. Lilly's defense: head-to-head trials are "the gold standard."

Chen's larger point is about management, not milligrams: this is the new, more aggressive Novo under CEO Mike Doustdar. "He's made Novo kind of more similar to Lilly," she said. Novo has embraced telehealth, launched a Wegovy subscription, and now reached for the courts.

The Street was unimpressed. On Squawk on the Street (July 21), Jim Cramer called it "apples versus oranges" and, in effect, sour grapes: "If they think their product is really better than Lilly's, my suggestion... is prove it. Go do a head-to-head." He pointed out that Lilly's ad is "right out of New England Journal of Medicine... I've yet to see them make a mistake in 40 years," and framed the suit as "an attempt at distraction." He bought more Lilly into the weakness. The Rundown (July 22) used the "sour grapes" line explicitly and noted the scoreboard: Lilly up about 50% over 12 months, Novo down about 24%.

Why it matters for the thesis: this is a proxy fight for who owns the metabolic franchise that is supposed to fund the next decade of pharma. The efficacy narrative belongs to Lilly (tirzepatide's dual mechanism, the SURMOUNT-5 head-to-head win). But Novo is not losing everywhere: on Morning Brew Daily (July 22), the oral pill segment noted that as of July 3, Novo's Wegovy pill had roughly 89% share and 153,000 US prescriptions, versus fewer than 20,000 for Lilly's oral. Novo launched months earlier and is "crushing" Lilly in orals. The real read is a split decision: Lilly leads on injectable efficacy and manufacturing scale; Novo leads on the oral launch it needed. A lawsuit does not change that balance, it just tells you how tense the market has become.

2. Lilly's "Amazonification," the clearest cliff-filling playbook we have

Last week the Lilly/Atai deal was fresh news. This week the podcasts dug into what it means.

On Biotech Hangout (episode 189, July 17), an industry BD veteran and analyst, Sam Fazeli, discussed what Fazeli dubbed the "Amazonification of pharma." Atai, $3.8B ($2.8B upfront plus a $1B contingent value right, or CVR, a payment that only lands if the drug hits future milestones) for an intranasal psychedelic (a form of DMT) in treatment-resistant depression, is just the latest move. The panel pointed to a recent Economist piece, "Lilly reinventing the pharma business," describing CEO Dave Ricks steering Lilly "closer to a tech company": a shift toward preventing disease rather than treating it, and a direct-to-consumer arm (Lilly Direct) that routes around the pharmacy middlemen (PBMs). Fazeli's point on the buying spree: Lilly is "going in every possible area of pharma," building deliberately against the day, "10 years down the road," when its obesity franchise plateaus. "Incredible urgency... proactivity is just remarkable."

BioCentury This Week (episode 378, July 21) put hard numbers on it. Atai is Lilly's 12th acquisition this year, bringing its total M&A upfront outlay to around $23 billion in seven months. It is one of Lilly's most clinically advanced buys of the year, and its second neuro takeout after Centessa ($6.3B upfront plus a $1.5B CVR, in narcolepsy). Atai's DMT sits behind Compass Pathways' psilocybin in treatment-resistant depression, and both trail J&J's Spravato, which "paved the commercial path" for this odd, clinic-administered class.

Why it matters: this is the template. A company with real firepower is not waiting for its cliff, it is spending years ahead of it, across many therapy areas, tolerating early-stage risk and using CVRs to bridge price gaps.

3. Pfizer, the "hamster wheel," and why Vertex gets a pass

The value-investing podcast Telltales (July 22) delivered the sharpest line of the week on cliff-exposed pharma. Pfizer was the poster child: it is "in a constant cycle on the hamster wheel of replacing their pipeline or replacing drugs that are falling off patent, having to do a lot of acquisitions, that's not a good place to be." Pfizer, they added, is "playing defense trying to replace revenue that's falling away," and pointedly, "the only one with debt on big pharma."

The contrast was Vertex, which they like: "on the smaller side of big pharma... grown by being good capital allocators... allocating for growth." They approve of Vertex's Crinetics acquisition if paltusotine hits its goals. On obesity they conceded Lilly "haven't put a foot wrong lately," but on valuation they actually prefer Regeneron.

Why it matters: this is the bear case on the cliff-exposed names, stated plainly. The market increasingly rewards growth allocators (Vertex, Lilly) and discounts defensive replacers (Pfizer). Are you buying to grow or buying to survive? That distinction is becoming the whole ballgame for how these stocks trade.

4. Biogen's anti-tau data, a messy "win" that unsettles neuro sentiment

The Biogen/Ionis Alzheimer's data (which broke around July 15) got a careful autopsy on BioCentury This Week (episode 378, July 21). Their drug Duranderson, an antisense oligonucleotide partnered with Ionis, targeting tau, technically missed its primary endpoint: it was supposed to show a dose-response on the CDR-SB cognitive scale, but the lowest dose (60mg every 24 weeks) actually worked best. Yet the absolute numbers looked respectable: 26% slowing on CDR-SB, 42% on ADAS-Cog13, 50% on the MMSE, which, as Selina Koch noted, line up "at least as good" as the approved anti-amyloid antibodies.

The catch is a genuine worry: the biomarkers showed a clean dose-response but cognition did not, raising the possibility of a "therapeutic window" above which stripping out too much tau (an important protein in neurons) does harm. Biogen is advancing to Phase 3 anyway; the market cap fell more than $2B on the day, and the panel's weary refrain was "haven't we seen this movie before?"

Why it matters: this keeps a lid on neuro/Alzheimer's sentiment (a read-through for Leqembi, Kisunla and the broader tau field), and it is exactly the kind of high-cost, binary Phase 3 bet that makes investors prefer companies buying de-risked assets (see: Lilly).

5. FDA changes its tune, and Lilly files a timeline for the next big thing

• FDA policy is reverting to normal. On BioCentury This Week (episode 378, July 21), Washington editor Steve Usdin reported that Acting FDA Commissioner Kyle Diamantis is vowing to abandon Marty Makary's "policy by podcast" approach and return to conventional guidance, communicated, ironically, through a private July 2 letter to Rep. Diana DeGette. It leaves ambiguity (for example, what standard CAR-T developers can rely on), but the direction is toward less regulation-by-improvisation, a quiet tailwind for the deal machine.
• Retatrutide has a date. On Bloomberg Intelligence (July 23), health reporter Madison Muller said Lilly plans to file its next-gen "Triple-G" drug retatrutide (GLP-1 + glucagon + GIP) for FDA approval in Q1 2027, with potential for up to 30% weight loss plus liver-fat benefits, the asset that could extend Lilly's obesity lead past any near-term Novo counter-punch.

The debate

The supercycle bull: The engine is intact and self-reinforcing. Lilly just showed the whole industry the playbook, 12 deals and roughly $23B of upfront M&A in seven months, and it is being rewarded for it. A more conventional, predictable FDA lowers deal friction. The firepower cohort has the cash to keep buying de-risked and early-stage assets years ahead of their cliffs. The GLP-1 franchise that funds much of this is expanding into orals, Medicare, and retatrutide. Every Phase 3 disappointment (Biogen this week) just pushes more capital toward buying innovation rather than building it, more demand for SMID-cap targets.

The cliff-erosion bear: Look past Lilly and the picture is defensive. Pfizer is a "hamster wheel," carrying debt and buying just to stand still. The names with the biggest holes, Merck, Bristol, J&J, AbbVie, were silent on strategy this week and just lost or sat out the deals that crossed the tape (Merck lost Personalis to Tempus). The obesity "firepower" story is now contested enough that its two champions are suing each other. And the market is punishing binary science: Biogen lost $2B in a day on a data set it calls a win. If the cliff-exposed incumbents cannot buy growth as efficiently as Lilly, the cliff erodes earnings faster than bolt-ons can refill them.

Our take: This was a "tale of two pharmas" week, and the gap between them widened. The story is no longer "will there be an M&A supercycle," that is settled; it is "who is deploying firepower offensively versus defensively," and the market is paying up for the former and discounting the latter. Lilly is running the offense so well that its problems are now legal (a rival's lawsuit) rather than operational. The names we'd watch most closely are the quiet ones, Merck, Bristol, AbbVie, into next week's earnings, because for them the absence of a bold move is itself the news. The Novo lawsuit is noise for the thesis: ignore the legal theater, watch the oral-pill share and the retatrutide clock.

Stocks in play

Currency note: NVO price target is in Danish kroner (DKK), not USD.

Read-throughs

• Likely takeout targets: The Lilly playbook is structurally bullish for SMID-cap sentiment. But note the pattern this week: the actual deals went to diagnostics/tools (Tempus/Personalis, $16.25/sh, ~$1.5B, all-stock, ~28% premium to 30-day VWAP) and CDMOs (Samsung Biologics/PolyPeptide, ~$1.8B, 40% premium, lower-confidence source), not classic biotech targets. Crinetics (Vertex) and Apogee (AbbVie) march toward Q3 closes. Endocrine and I&I remain the hot adjacencies.
• Biosimilar / generics makers: A macro overhang appeared, a July 22 report that the US may impose a 100% tariff on imported generic drugs (thefly). That is a cost shock for the generic/biosimilar supply chain that erodes branded cliffs (Eliquis, Stelara, Humira aftermath).
• SMID sentiment / XBI: GLP-1 dominates consumer podcasts, but institutional attention was on M&A structure and a couple of disappointments (Biogen, Summit). Constructive but selective, capital chasing de-risked assets, punishing binary bets.
• Bankers / CROs: Deal velocity stays high; a reverting, predictable FDA plus Lilly's serial-buyer cadence keep the pipeline full. BioCentury's CRO-executive note on the UK's "two economies" (northern England trial costs far below the south, capabilities just as strong) is a reminder that trial-cost arbitrage is a live CRO-margin theme.

What changed vs last week

• New anchor: Last week's story was the accelerating M&A supercycle (roughly 46-day closes). This week the loudest story flipped to the Novo-versus-Lilly lawsuit and a deep-dive on Lilly's "Amazonification."
• Personalis (PSNL), rumor became a deal, but not Merck's. Last week we flagged Merck plus two or more suitors. This week Tempus AI is buying Personalis ($16.25/sh, ~$1.5B, all-stock, no CVR, ~28% premium to 30-day VWAP), and Merck signed a voting agreement to support Tempus with its ~13% stake. A standalone Merck buyout is moot, Merck stayed disciplined.
• China Select Committee probe, the deadline passed quietly. July 17 was the deadline for ABBV/BMY/LLY/MRK/PFE to hand over China clinical-trial records. As of today, responses are not public and Chairman Moolenaar has made no new statements on the probe. Slow burn, still an overhang into earnings.
• AZN/Ionis eplontersen: No new data; full CARDIO-TTRansform results still due at ESC Congress in late August (missed composite endpoint; monotherapy subgroup HR 0.71).
• Deals progressing to close: Vertex/Crinetics ($10.0B, $85/sh) filed HSR (7/20) and a preliminary proxy (7/21), on track for Q3. AbbVie/Apogee ($10.9B, $135.11/sh) set a stockholder vote for Aug 11.
• New this week: generic-drug 100% tariff threat; Lilly retatrutide Q1'27 filing timeline; Novo EU oral-Wegovy approval; FDA "policy by podcast" reversal; RVMD FDA filing acceptance; GILD Leerink downgrade; SMMT Q2 miss and PT cuts.
• Still open: Abivax (ABVX) re-engaged Centerview after a roughly EUR 800M raise (process, no deal). Sangamo (SGMOQ) Chapter 11, DIP hearing set 7/21 (outcome unconfirmed), creditors' meeting 7/28; Lilly and Astellas are stalking-horse bidders. Insmed (INSM): no new Brinsupri data, but BMO initiated Outperform at $192 (7/20).